|
CEOCFO MOBILEÂ 我爱酸酸乳ssr免费节点 免费ssr节点2022Â |Â Â CEOCFO-SERVICES |Â HOME |
||
|
ssr免费订阅地址 |
CEOCFO-科学上外网 ssr |
|
October 29, 2018 Issue |
||
|
CEOCFO MAGAZINE |
||
|
 |
||
|
SSR免流+加速一体方案新司机不坐公交车必备！-Mac论坛 ...:2021-2-26 · 手机下载ssr软件，账号填上 输入混淆参数 x-online-host:wap.10010.com(根据运营商改host) 4.安装加速软件 1.什么是锐速 一种只需单边部署就可伍起到显著加速效果的 TCP 加速技术,是目前业界唯 … |
 | |
|
 http://www.onconova.com/  Interview conducted by: Bud Wayne, Editorial Executive CEOCFO Magazine, Published – October 29, 2018  CEOCFO: Dr. Fruchtman, Mr. Guerin, we have had the pleasure of speaking with your CEO Dr. Kumar over the past few years, so would you introduce yourselves to our readers. How long have you been with Onconova, and what attracted you? Dr. Fruchtman, as President and CMO, what is your day-to-day role at Onconova? Are you heavily involved in running the business, as well as for example clinical trials and product development? Dr. Fruchtman: I have been with Onconova for approaching four years. There were two things that attracted me to Onconova. First was the space we are studying, which is known as Myelodysplastic Syndrome or MDS, and also referred to as pre-leukemia. I have always had an interest in bone marrow diseases. At one point in my career I ran the Bone Marrow Transplant Service at Mt. Sinai Hospital, a procedure that  replaces bone marrow infiltrated with diseases such as leukemia or MDS with normal marrow stem cells, by replacing the diseased poorly function bone marrow with somebody else’s bone marrow. Clearly a preferable route is to develop medications to improve bone marrow function rather than putting a patient through a very rigorous transplant therapy where stem cells come from a normal donor infused into the patient. At Onconova we are developing new drugs for Myelodysplastic Syndrome (MDS). The second thing that attracted me to Onconova was leadership. I was very impressed with the senior management; they had been in big pharma, small pharma, and clearly had a passion to get novel drugs approved for cancer. My day at Onconova is always very interesting and exciting. We are running a global trial with the goal of randomizing 360 patients with high-risk MDS. When you are running a global trial of such magnitude and importance there are always regulatory questions and clinical questions about the patients on your experimental drug or control arm. That is how I have managed most of my day as Chief Medical Officer. Since my promotion to president, I have also gotten more involved with the business aspects of running a small biotech company and that has been of great interest to me as well.  CEOCFO: Mr. Guerin, are you strictly a numbers guy as or do you play an extend role as well in your function as CFO? Mr. Guerin: I do more than just the numbers. Most of my time is spent on things involving numbers but not just preparing financial statements. I am responsible for the financial reporting and tax reporting. I also take care of all of our forecasting and projections, as well as critical financing transactions that we consider, as well as business development deals, looking at potential license partners, negotiating term sheets, drafting final agreements, and additional similar responsibilities. From an operations standpoint, I support our clinical team by helping review contracts and negotiating contracts involving consultants or manufacturers. I am also involved in and responsible for human resources, administrative and IT functions.  CEOCFO: Onconova has three product candidates in clinical trials and several active pre-clinical programs, with your lead compound, Rigosertib, are aimed at unmet medical needs of patients with myelodysplastic syndromes (MDS). Let us talk first about Rigosertib. How is it different from any other therapeutic approaches to MDS? Dr. Fruchtman:SSR安卓客户端和PC客户端的详细使用教程和常见问题 ...:2021-5-20 · 2 PC端SSR版本的选择 3 PC端SSR配置信息 4 PC端SSR启用伋理 5 安卓端SSR的设置 5.1 常规添加 5.2 二维码添加 5.3 文本导入添加 6 关于PC端SSR一些功能的说明 7 你可能会遇到的一些问题 锐速:VPS安装锐速 锐速一键脚本 锐速一键安装包 Linux锐速 ...:2021-5-26 · Linux锐速开心版一键安装脚本+源码 当我伊购买外国服务器使用时可伍说是比较卡,尤其是那些挂小水管,的更是抱怨不停,此时锐速拯救了我伊可是不幸的是, 他伊现在已经停止注册,客人是我伊还想注册怎么办？没办法谁让这个是CHINA 今天为大家打来破解 This is the mechanism of action of rigosertib, and hopefully to be proven in a randomized trial in Myelodysplastic Syndrome that it can prolong the survival of these patients.  CEOCFO: Would you explain MDS? Is it a precursor to leukemia; are they linked as disease states? Is it a disease to affects mainly the ageing population? Dr. Fruchtman: MDS was previously referred to as pre-leukemia and that perhaps was a better term and easier to understand. But since many patients do not develop acute leukemia the 星光加速ssr people have a concept of what leukemia is; most people do not have a concept of what MDS is. In both conditions; perhaps due to viruses or environmental toxins, or just associated with the aging process, the bone marrow cells begin to accumulate genetic abnormalities and these genetic abnormalities go on to create replicating leukemia cells in the bone marrow. This occurs in both Myelodysplastic Syndrome, and in acute leukemia, in both the bone marrow and the peripheral blood. So there is a transition between MDS and acute leukemia based solely on how many of these leukemia cells are in the bone marrow. Myelodysplastic Syndrome has fewer leukemia cells in the marrow, and when the leukemia cells increase in the marrow, then the disease is called acute leukemia. Obviously acute leukemia has a poor prognosis but there are patients with MDS that also have a very poor prognosis. That is the differentiation between MDS and acute leukemia; it is determined by how many leukemia cells are in the bone marrow of the patient.  The other key question you asked is one that is posed regularly, which is whether MDS is a disease of the elderly. The answer is yes. The mean age is about 65, but unfortunately there are also children who develop an MDS type syndrome which is somewhat different in these children. We anticipate that Rigosertib, at some point in 2023, in association with the National Cancer Institute in Bethesda, Maryland, and their Pediatric Oncology Branch, we will be giving Rigosertib to children that have leukemia that is RAS mutated, or other cancers that these children develop that are also caused by the mutated RAS gene. So we anticipate studying Rigosertib in these children at some point in 2023. The clinical trial that we have ongoing with Rigosertib, the INSPIRE trial, is a Pivotal Phase 3 trial. That means that on the basis of this trial, in negotiation with United States FDA and the European EMA, if the overall survival endpoint is prolonged in a significant fashion, i.e. the life expectancy of patients with MDS when randomized to Rigosertib is improved, we will have a pathway for regulatory approval and opportunity to commercialize Rigosertib. That is why it is called a Pivotal Trial and we are currently conducting an international Pivotal Trial for patients with Myelodysplastic Syndrome who failed the standard of care, which is a hypomethylating agent. Once a patient fails a hypomethylating agent with high-risk Myelodysplastic Syndrome, there is no FDA or EMA approved drug in the world, so that is where we hope Rigosertib will be able to help these patients. We anticipate the completion of this Pivotal Trial in approximately another year. That is for the adult patients with MDS.  免费ssr机场 Would you tell us about your Rigosertib and azacitidine combination trial and where you are today? Dr. Fruchtman:ubuntu 安装 bbr 更好的加速你的国外VPS - 搬瓦工教程网:2021-1-4 · 搬瓦工官网 免费SS 帐号 RSS订阅 当前位置： 搬瓦工VPS, bwh1, BandwagonHost > VPS教程 > 正文 ubuntu 安装 bbr 更好的加速你的国外VPS ...  星辰加速 shadow What is the purpose of the Phase 2 trials? What are you looking to see? Dr. Fruchtman: The idea of doing a Phase 2 is to see the response of the combination and help to determine the optimal dose. Once a response appears to be impressive, and the optimal dose of the combination is determined, then we plan to take that information into a new Pivotal Phase 3 trial, which would be the combination of Azacitidine plus oral Rigosertib verses the control arm, which would be the FDA approved single agent of Azacitidine plus oral placebo. We anticipate based on our need for additional funding, to open up a new Pivotal Phase 3 trial of this novel doublet at some point in 2023.  CEOCFO: Are there any other trials with regard to Rigosertib or what you are working on that we should be aware of? Dr. Fruchtman: Based on the mechanism of action of Rigosertib involving the RAS pathway and on preclinical models, we are exploring studying Rigosertib in K-RAS mutated lung cancer. For patients with this disease, one of the new therapies available are immuno-oncology drugs, also referred to as Checkpoint inhibitors. The next step will be to initiate a new Phase 1 trial looking at Rigosertib in K-RAS mutated lung cancer, perhaps in association with an immuno-oncology agent. Also in 2023, as I mentioned, we anticipate studying children who have RAS driven cancers, in collaboration with the National Cancer Institute. In addition to Rigosertib, our scientists have an agent early in development referred to as ON 123300. This is a molecule that targets a pathway referred to as a Cyclin-dependent kinase (CDK) 4/6 pathway, along with the ARK 5 pathway. Drugs that target Cyclin 4/6, are commonly used for women with metastatic breast cancer, and they are approved for that indication, in combination with an Aromatase inhibitor. We have begun pre-IND studies, toxicology studies in a number of animal models to determine efficacy and safety in these models. We anticipate in early 2023 to file an IND with the US FDA, and to initiate the first in human trial with ON 123300. Briciclib and Recilisib are two additional agents we have in our portfolio; both of them have very interesting mechanisms of action but will require additional funding for programs studying these drugs.  星光加速ssr: Onconova has patients enrolled in clinical trials in the United States, Europe, Japan and Australia? Was this accomplished through partnering? What does it take to accomplish an operation that is so massive and then run it? Dr. Fruchtman:CentOS 7 开启 BBR 加速 - 云+社区 - 腾讯云:2021-3-2 · Google 在 2021年9月伇开源了他伊的优化网络拥堵算法BBR，最新版本的 Linux内核（4.9-rc8）中已经集成了该算法。 对于TCP单边加速，并非所有人都很熟悉，不过有另外一个大名鼎鼎的商业软件“锐速”，相信很多人都清楚。  酸酸乳ssr网站 Running such an operation with worldwide clinical trials takes a great deal of resources. You closed a $28.75 Million upsized underwritten public offering recently, would you tell us about that and other fund raising efforts, as well as where you are today with your financing? Are you continually looking for partners and investors? Mr. Guerin: We closed a nearly $29 million offering in early May of 2018. As you mentioned that was an underwritten and upsized public offering. Prior to that in mid-February we raised about $10 million in another public offering. Therefore, in the first four months of the year we raised approximately $40 million. We are excited about those financings not just because they brought us the capital that they did, but because they also brought in some key investors who are biotech focused investors and not only hedge fund type investors. That is good because when people like that invest in a biotech offering, they generally do a fair amount of diligence and they are generally long. We were excited to upgrade our investor base with these offerings. The other thing about it is that without raising any additional money, and if our cash burn stays the same, our cash will last us to the 4th Quarter of 2023. The reason that is important is because we have a number of milestones between now and then and most notably top line data in our INSPIRE study; which we expect in the second half of 2023. Because of our cash position, we are not currently planning on a financing, although we have been actively pursuing business development deals over the past year or so. Some of that you saw come to fruition in December of 2017, when we signed a deal with a company called HanX Biopharma for our CDK4/6 compound, our ON 123300 agent. Then in January of 2018 we signed our collaborative research and development arrangement with the National Cancer Institute, and in March of 2018 we signed a deal with Pint for Latin America for Rigosertib. We remain active in pursuing partners and we do expect that we will be able to get some more regional partnerships over the coming months.  CEOCFO: 老张的技术博客:2021-3-2 · 前言 看见好多人搭建网站需要虚拟主机，但是网上免费的要么不稳定，搞得三天两头数据丢失。要么盗窃用户数据，但是收费的又不划算，不够自己搭建其他网站使用，所伍今天教大家如何用服务器 … 科学上外网 ssr Between Steve, our CEO and myself, we present at conferences and meetings together. Sometimes it is two of us and sometimes it is just one of us. We are able to cover a lot of different conferences and meetings with this approach. Right now our CEO, Dr. Ramesh Kumar, PhD is at the BIO Investor Forum in San Francisco. That is happening as we speak. One of the most important upcoming conferences and meetings for us will be the American Society of Hematology in December this year. Steve will tell you about that conference. Dr. Fruchtman: That is the most important Malignant and Benign Hematology Conference in the world. It happens once a year, typically the first week in December. This year it is in San Diego. One of the featured presentations always are abstracts on Myelodysplastic Syndrome, acute leukemia and new drug development, so we will have a robust team at ASH to participate in their MDS conference as well.  CEOCFO: Onconova announced a reverse stock split? What was that meant to accomplish and how will it help you going forward? Mr. Guerin: We announced that in September 25th. The reason we did the reverse split is because as you and many of your readers probably know, to maintain our listing on the Nasdaq capital markets exchange, we need to have closing bid price that is over a dollar. Earlier in 2018 our stock price went below a dollar and we got a notice of that fact from Nasdaq that we had 180 days to remedy that. The most common way that biotech companies fix that problem is with a reverse split. In our annual shareholder meeting in June of this year, our shareholders approved of us doing a reverse split at the discretion of the board. We executed that reverse split in September and the result is that we just filed an 8-K on Monday of this week announcing that we had received a letter from Nasdaq acknowledging that we were back in compliance with their continued listing requirements. We were successful in addressing that non-compliance, and we remain listed on Nasdaq.  CEOCFO: What can we expect over the next year, and why do you think Onconova is a special company? 锐速加速ssr We have some very important and influential milestones coming up in the next year. One is we anticipate full accrual in the second half of 2023 to our INSPIRE trial in high-risk MDS, studying intravenous Rigosertib. We anticipate our data from the combination trial of oral Rigosertib to be presented at a major medical meeting towards the end of 2018. We anticipate in early mid-2023 to have a first pediatric patient with a RAS driven cancer to be put on a study with Rigosertib as well. In addition in 2023, we anticipate a first in human trial with our research drug ON 123300. Therefore, we have some very important milestones towards the end of 2018 and 2023 as well. Mr. Guerin: The other thing that I would add is at any point or at many points between now and the end of 2023, we should expect to close business development deals for certain geographies. I mentioned before that we have been pursuing that for a while, and as we achieved the milestone Steve just mentioned, we will also be making progress on business development deals. I expect to see some of them coming in, as well.  |
“Onconova has key milestones in the upcoming year, that can change the landscape of the treatment of MDS; which include full accrual to a pivotal phase 3 trial with intravenous rigosertib in patients who fail the standard of care, and also data in first line MDS of the combination of oral rigosertib with the standard of care in a study designed to optimize the response rate.”
Onconova http://www.onconova.com/ Â Contact: Mark Guerin, CFO 267-759-3680 mguerin@onconova.us
Latest News
 锐速/BBR/魔改BBR/KCPTUN加速效果对比测试-翻墙党:2021-5-14 · 不足： 不支持OpenVZ架构的系统安装；不支持部分系统内核安装。 锐速一键安装：锐速一键安装脚本，附加速40倍效果图 锐速Windows版下载：锐速Windows破解版下载安装及使用教程 附加速23倍效果图 原版BBR 优点： 官方新内核集成不占用系统资源，安装成功率高，TCP加速效果比较明显，可伍对网站 ...  Onconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New Zealand  Onconova Therapeutics and Pint Pharma Announce Brazilian Health Authority Approval for Initiating INSPIRE Trial with Intravenous Rigosertib in Higher-Risk Myelodysplastic Syndromes in Brazil  Onconova Therapeutics, Inc. Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-Market  锐速:VPS安装锐速 锐速一键脚本 锐速一键安装包 Linux锐速 ...:2021-5-26 · Linux锐速开心版一键安装脚本+源码 当我伊购买外国服务器使用时可伍说是比较卡,尤其是那些挂小水管,的更是抱怨不停,此时锐速拯救了我伊可是不幸的是, 他伊现在已经停止注册,客人是我伊还想注册怎么办？没办法谁让这个是CHINA 今天为大家打来破解
Onconova Therapeutics Announces Presentations at the 24th Congress of the European Hematology Association
Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2023 Financial Results  Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and Commercialize Rigosertib in Greater China  Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2023 Financial Results  Onconova Therapeutics Announces Presentations at the 15th International Symposium on Myelodysplastic Syndromes (MDS 2023) in Copenhagen, Denmark  Onconova Therapeutics to Present Update at the 2023 HCW Global Life Sciences Conference in London, April 7-9  Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results
Onconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018 Â 搬瓦工VPS锐速及BBR安装 - 搬瓦工-搬瓦工VPS中文网:2021-3-23 · 目前大家比较认可的搬瓦工网络优化方案分别是锐速及google BBR，其中Google BBR默认添加到系统版本，我伊使用的时候选择带_BBR后缀的系统即可。这里有一点需要注意，由于锐速与BBR要求的linux 内核版本不一样，所伍两者不能共存，只能选择其中一种使用。所伍本文同时介绍2种方法，供大 … Â
Onconova Announces Four Presentations
from Rigosertib Clinical Trials in Myelodysplastic Syndromes (MDS) at the
2018 ASH Annual Meeting & Exposition  Onconova Therapeutics to Meet with Potential Investors and Business Development Partners at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark  Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib  锐速:VPS安装锐速 锐速一键脚本 锐速一键安装包 Linux锐速 ...:2021-5-26 · Linux锐速开心版一键安装脚本+源码 当我伊购买外国服务器使用时可伍说是比较卡,尤其是那些挂小水管,的更是抱怨不停,此时锐速拯救了我伊可是不幸的是, 他伊现在已经停止注册,客人是我伊还想注册怎么办？没办法谁让这个是CHINA 今天为大家打来破解
|
|
| Â | ||
|
disclaimers |
||
| Â | ||
|
 |
||
|
搬瓦工VPS锐速及BBR安装 - 搬瓦工-搬瓦工VPS中文网:2021-3-23 · 目前大家比较认可的搬瓦工网络优化方案分别是锐速及google BBR，其中Google BBR默认添加到系统版本，我伊使用的时候选择带_BBR后缀的系统即可。这里有一点需要注意，由于锐速与BBR要求的linux 内核版本不一样，所伍两者不能共存，只能选择其中一种使用。所伍本文同时介绍2种方法，供大 … |
||
|
 |
||
          Â
